Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 180

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 180
---
 PTK7, there are multiple PTK7 programs currently in, or about to begin, clinical development, some of which are described here:

| • |     | PRO1107, being developed by Genmab following its acquisition of ProfoundBio, is currently in Phase 1/2 with the                                                                                                   
 first patient dosed in February 2024. PRO1107 uses an MMAE payload, which is a tubulin inhibitor similar to the payload in Cofe-P, connected through a protease-cleavable hydrophilic linker system called LD343, 
 and has a DAR of 8.                                                                                                                                                                                               |

| • |     | DAY301 (MTX-13), being developed by Day One Biopharmaceuticals after                                                                                                                                              
 acquiring development and commercialization rights outside of the Greater China area from MabCare Therapeutics, recently initiated a Phase 1 trial. Unlike Cofe-P and PRO1107, DAY301 has a pure exatecan payload 
 which may be associated with myelosuppression. LY4175408, being developed by Eli Lilly, also has a pure exatecan payload. We expect Eli Lilly will submit its IND in 2025.                                        |

| • |     | SKB518, being developed by Kelun Biotech, is currently in Phase 1 in China. |

We expect multiple external PTK7 ADC programs are projected to present clinical data in 2025 to 2027, which will further validate our target and TOPO1 inhibitor payload approach. Additionally, there are multiple preclinical PTK7 bispecific ADCs in development, including the PTK7 x B7-H3ADC recently acquired by IDEAYA Biosciences. There are a number of other ADC programs in development for NSCLC targeting other tumor-associated antigens. Our Product Candidate: PTK7-CPT113 PTK7-CPT113, as a differentiated next wave PTK7-directed ADC, is poised to be among the first in next wave ADCs with an alternate TOPO1 inhibitor payload to enter the clinic. With its optimized linker and TOPO1 payload switch, we are targeting to build on the initial ORRs seen with Cofe-pand potentially deliver superior outcomes for patients. PTK7-CPT113 has already demonstrated superior tumor reduction compared to Cofe-pin both in vitroand in vivopreclinical models. PTK7-CPT113 shows superior tumor reduction in a lung cancer cell lines compared to similar doses of C